[Skip to Content]
[Skip to Content Landing]
Views 728
Citations 0
Viewpoint
April 2016

Addressing Skyrocketing Cancer Drug Prices Comes With TradeoffsPick Your Poison

Author Affiliations
  • 1Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington
  • 2Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington
  • 3Patient Advocacy Committee, SWOG, Portland, Oregon
JAMA Oncol. 2016;2(4):425-426. doi:10.1001/jamaoncol.2015.5813

As oncology drug costs continue to rise and many patients experience financial distress in part owing to out-of-pocket drug costs, calls to reduce oncology drug prices are gaining public support and political traction.1,2 However, politically viable policy interventions will not be free and will entail tradeoffs that may reduce patient access to cancer medications.

First Page Preview View Large
First page PDF preview
First page PDF preview
×